You are here:

Category: 8.1 Cytotoxic drugs

Name SMC ID No Manufacturer Status Sub. Type
 
afatinib (Giotrif) 1174/16 Boehringer Ingelheim Ltd Not Recommended Non submission
afatinib (Giotrif) 920/13 Boehringer Ingelheim Ltd Accepted Full submission
aflibercept (Zaltrap) 878/13 Sanofi-Aventis Not Recommended Full submission
aflibercept (Zaltrap) 878/13 Sanofi-Aventis Accepted Resubmission
alectinib hydrochloride (Alecensa) 1257/17 Roche Not Recommended Non submission
axitinib (Inlyta) 855/13 Pfizer Ltd Accepted Resubmission
azacitidine (Vidaza) 589/09 Celgene Ltd Not Recommended Full submission
azacitidine (Vidaza) 589/09 Celgene Ltd Accepted Resubmission
azacitidine (Vidaza) 1175/16 Celgene Ltd Not Recommended Non submission
bendamustine (Levact) 700/11 Napp Pharmaceuticals Ltd Not Recommended Non submission
bendamustine (Levact) 701/11 Napp Pharmaceuticals Ltd Not Recommended Non submission
bendamustine hydrochloride (Levact) 694/11 Napp Pharmaceuticals Ltd Accepted Full submission
bevacizumab (Avastin) 778/12 Roche Not Recommended Full submission
bevacizumab (Avastin) 806/12 Roche Not Recommended Full submission
bevacizumab (Avastin) 806/12 Roche Not Recommended Resubmission
bevacizumab (Avastin) 806/12 Roche Restricted Resubmission
bevacizumab (Avastin) 853/13 Roche Not Recommended Full submission
bevacizumab (Avastin) 1135/16 Roche Accepted Full submission
bevacizumab (Avastin) 1190/16 Roche Not Recommended Non submission
bevacizumab (Avastin) 1063/15 Roche Restricted Full submission
bevacizumab (Avastin) 425/07 Roche Not Recommended Non submission
bevacizumab (Avastin) 459/08 Roche Superseded Non submission
bevacizumab (Avastin) 469/08 Roche Superseded Full submission
Bevacizumab 100mg/4ml and 400mg/16ml solution for intravenous infusion (Avastin®) 221/05 Roche Not Recommended Full submission
Bevacizumab 100mg/4ml and 400mg/16ml solution for intravenous infusion (Avastin®) 221/05 Roche Not Recommended Resubmission
Bevacuzimab (Avastin) 387/07 Roche Not Recommended Non submission
Bexarotene (Targretin®) 14/02 Ligland/Elan Restricted Full submission
bortezomib (Velcade) 302/06 Ortho Biotech Accepted Resubmission
bortezomib (Velcade) 822/12 Janssen-Cilag Ltd Accepted Abbreviated Submission
bortezomib (Velcade) 1075/15 Janssen-Cilag Ltd Accepted Full submission
bortezomib (Velcade) 927/13 Janssen-Cilag Ltd Restricted Full submission
bortezomib (Velcade) 3.5mg powder for intravenous injection 302/06 Ortho Biotech Not Recommended Full submission
Bortezomib (Velcade®) 126/04 Ortho Biotech Accepted Full submission
bortezomib, 3.5mg vial of powder for solution for intravenous injection (Velcade) 302/06 Ortho Biotech Not Recommended Resubmission
bosutinib (Bosulif) 910/13 Pfizer Ltd Accepted Resubmission
brentuximab vedotin (Adcetris) 845/12 Takeda UK Ltd Restricted Full submission
busulfan, 6mg/ml, intravenous (Busilvex) 337/06 Pierre Fabre Ltd Accepted Full submission
cabazitaxel (Jevtana) 735/11 Sanofi-Aventis Not Recommended Full submission
cabazitaxel (Jevtana) 735/11 Sanofi-Aventis Not Recommended Resubmission
cabazitaxel (Jevtana) 735/11 Sanofi-Aventis Restricted Resubmission
cabozantinib (Cabometyx) 1234/17 Ipsen Ltd Accepted Full submission
cabozantinib (Cometriq) 1022/15 Swedish Orphan Not Recommended Full submission
capecitabine (Xeloda) 507/08 Roche Accepted Full submission
capecitabine (Xeloda) 716/11 Roche Accepted Full submission
Capecitabine (Xeloda®) 34/03 Roche Restricted Full submission
Capecitabine 150 and 500mg tablets (Xeloda®) 193/05 Roche Accepted Full submission
capecitabine 150mg and 500mg tablets (Xeloda) 401/07 Roche Accepted Full submission
carfilzomib (Kyprolis) 1171/16 Amgen Ltd Not Recommended Resubmission
carfilzomib (Kyprolis) 1171/16 Amgen Ltd Not Recommended Full submission
Carmustine implant (Gliadel®) 215/05 Link Pharmaceuticals Ltd Accepted Full submission
catumaxomab (Removab) 788/12 Fresenius Medical Care (UK) Ltd Not Recommended Non submission
ceritinib (Zykadia) 1097/15 Novartis Pharmaceuticals UK Ltd Accepted Full submission
cetuximab (Erbitux) 155/05 Merck Serono Ltd Superseded IRP
cetuximab (Erbitux) 155/05 Merck Serono Ltd Superseded Full submission
cetuximab (Erbitux) 547/09 Merck Serono Ltd Not Recommended Non submission
cetuximab (Erbitux) 543/09 Merck Serono Ltd Superseded Full submission
cetuximab (Erbitux) 543/09 Merck Serono Ltd Superseded Resubmission
cetuximab (Erbitux) 1012/14 Merck Serono Ltd Superseded Full submission
cetuximab 2mg/ml intravenous infusion (Erbitux) 279/06 Merck KGaA Restricted Full submission
cladribine (LITAK) 537/09 LIPOMED GmbH Accepted Abbreviated Submission
clofarabine, 1mg/ml concentrate for solution for infusion (Evoltra) 327/06 Bioenvision Limited Restricted Full submission
crizotinib (Xalkori) 865/13 Pfizer Ltd Not Recommended Full submission
crizotinib (Xalkori) 865/13 Pfizer Ltd Accepted Resubmission
crizotinib (Xalkori) 1152/16 Pfizer Ltd Accepted Full submission
dabrafenib (Tafinlar) 1023/15 GlaxoSmithKline UK Ltd Restricted Full submission
dasatinib (Sprycel) 1170/16 Bristol-Myers Squibb Pharmaceuticals Ltd Accepted Full submission
dasatinib (Sprycel) Second Line Treatment 370/07 Bristol-Myers Squibb Pharmaceuticals Ltd Accepted Resubmission
dasatinib 20mg, 50mg, 70mg tablets (Sprycel) 371/07 Bristol-Myers Squibb Pharmaceuticals Ltd Not Recommended Full submission
dasatinib 20mg, 50mg, 70mg tablets (Sprycel) 370/07 Bristol-Myers Squibb Pharmaceuticals Ltd Superseded Full submission
decitabine (Dacogen) 846/12 Janssen-Cilag Ltd Not Recommended Non submission
dexrazoxane 20mg/ml, for infusion (Savene) 361/07 TopoTarget A/S Not Recommended Full submission
dexrazoxane (Cardioxane) 419/07 419/07 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
dexrazoxane (Savene) 361/07 TopoTarget A/S Not Recommended Resubmission
docetaxel (Taxotere) 659/10 Sanofi-Aventis Not Recommended Non submission
docetaxel (Taxotere) 481/08 Sanofi-Aventis Restricted Full submission
docetaxel (Taxotere) injection concentrate 333/06 Sanofi-Aventis Not Recommended Non submission
Docetaxel (Taxotere®) 42/03 Aventis Restricted Full submission
docetaxel 20 and mg concentrate and solvent for solution for infusion (Taxotere) 369/07 Sanofi-Aventis Restricted Full submission
Docetaxel 20mg, 80mg concentrate and solvent for solution for infusion, single dose vials (Taxotere®) 201/05 Sanofi-Aventis Accepted Full submission
Docetaxel concentrate and solvent for solution for infusion, single dose vials (Taxotere®) 209/05 Sanofi-Aventis Superseded Full submission
eribulin (Halaven) 1065/15 Eisai Ltd Restricted Resubmission
eribulin (Halaven) 1065/15 Eisai Ltd Not Recommended Full submission
eribulin mesylate (Halaven) 726/11 Eisai Ltd Not Recommended Full submission
erlotinib (Tarceva) 664/10 Roche Not Recommended Full submission
erlotinib (Tarceva) 749/11 Roche Accepted Full submission
Erlotinib (Tarceva) 382/07 Roche Not Recommended Non submission
Erlotinib (Tarceva®) 220/05 Roche Superseded Resubmission
Erlotinib (Tarceva®) 220/05 Roche Not Recommended Full submission
everolimus (Afinitor) 595/10 Novartis Pharmaceuticals UK Ltd Not Recommended Full submission
everolimus (Afinitor) 872/13 Novartis Pharmaceuticals UK Ltd Accepted Resubmission
everolimus (Afinitor) 872/13 Novartis Pharmaceuticals UK Ltd Not Recommended Full submission
everolimus (Afinitor) 872/13 Novartis Pharmaceuticals UK Ltd Not Recommended Resubmission
everolimus (Afinitor) 777/12 Novartis Pharmaceuticals UK Ltd Superseded Full submission
everolimus (Afinitor) 1215/17 Novartis Pharmaceuticals UK Ltd Superseded Full submission
everolimus (Afintor) 595/10 Novartis Pharmaceuticals UK Ltd Accepted Resubmission
everolimus (Certican) 1117/15 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
everolimus (Votubia) 787/12 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
everolimus (Votubia) 884/13 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
fludarabine, 10mg tablet and 50mg for injection or infusion (Fludara) 176/05 Schering Health Care Ltd Restricted Full submission
gefitinib (Iressa) 615/10 AstraZeneca UK Ltd Not Recommended Full submission

Back